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Acute Infantile Liver Failure
Due to Mutations in the TRMU Gene
Avraham Zeharia,1,4,9 Avraham Shaag,1,9 Orit Pappo,2 Anne-Marie Mager-Heckel,5 Ann Saada,1
Marine Beinat,6 Olga Karicheva,5 Hanna Mandel,7 Noa Ofek,3 Reeval Segel,8 Daphna Marom,4
Agnes Ro¨tig,6 Ivan Tarassov,5 and Orly Elpeleg1,*
Acute liver failure in infancy accompanied by lactic acidemia was previously shown to result from mtDNA depletion. We report on 13
unrelated infants who presented with acute liver failure and lactic acidemia with normal mtDNA content. Four died during the acute
episodes, and the survivors never had a recurrence. The longest follow-up period was 14 years. Using homozygosity mapping, we iden-
tiﬁed mutations in the TRMU gene, which encodes a mitochondria-speciﬁc tRNA-modifying enzyme, tRNA 5-methylaminomethyl-2-
thiouridylate methyltransferase. Accordingly, the 2-thiouridylation levels of the mitochondrial tRNAs were markedly reduced. Given
that sulfur is a TRMU substrate and its availability is limited during the neonatal period, we propose that there is a window of time
whereby patients with TRMU mutations are at increased risk of developing liver failure.Acute liver failure in infancy is a life-threatening condition
manifested by poor feeding, vomiting, jaundice, distended
abdomen, hemorrhagic diathesis, irritability, and hypoac-
tivity. Routine laboratory investigations reveal elevated
liver transaminases, hypoglycemia, coagulopathy, hyper-
ammonemia, and direct hyperbilirubinemia. The differen-
tial diagnosis includes viral infections, intoxications, and
inborn errors of metabolism. The ﬁnding of hyperlactate-
mia directs the diagnosis toward mitochondrial respiratory
chain disorders, and in about half of the patients there is
a defect in the mtDNA synthesis machinery, resulting in
mtDNA depletion (MIM 251880). This was heretofore
attributed to mutations in three genes: DGUOK (MIM
601465), POLG (MIM 174763), and MPV17 (MIM
137960).1–3
In the past 14 years, we have encountered eight patients
in seven unrelated families of Yemenite Jewish origin, who
presented in infancy with acute liver failure. All were born
at term, had birth weights appropriate for gestational age,
and had physiologic hyperbilirubinemia that resolved in
a normal manner. All were reportedly healthy during the
early neonatal period but were admitted at 2–4 months
because of irritability, poor feeding, and vomiting. On
physical examination, all were found to be well-nourished
but lethargic, with pale-gray skin color, jaundiced sclerae,
distended abdomen, and hepatomegaly. All of the patients
required intensive care for several weeks, with supportive
nutrition and blood products given as compensation for
coagulopathy and active GIT bleeding. Liver transplanta-
tion was considered but was not performed in any of the
patients.The AmericanLaboratory investigation disclosed acute liver failure
(clinical and biochemical data presented in Table 1) with
severe coagulopathy that included low factor 5 and 11
and was not corrected by vitamin K supplementation, low
albumin,directhyperbilirubinemia,metabolic acidosis, hy-
perlactatemia, andhigh alpha-fetoprotein. Blood ammonia
level was normal or slightly elevated, and plasma amino
acid proﬁle was noted for high phenylalanine, tyrosine,
methionine, glutamine, and alanine. Urinary organic acid
analysis revealed massive excretion of lactate, phenylala-
nine and tyrosine metabolites, and ketotic dicarboxylic
and 3-hydroxydicarboxylic aciduria. Serology for hepatitis
viruses and body ﬂuid cultures failed to detect an infectious
etiology. Abdominal ultrasound disclosed enlarged homog-
enous liver with normal diameter of the bile ducts and the
portal vein.
Clinical and biochemical improvement started after
2–3 weeks, and liver functions returned to normal within
3-4 months. Nonetheless, liver size had normalized only
after 3months to 3 years. Seven patients survived the acute
episode, were observed on a long term follow-up (the old-
est currently 14 years of age) to be developing normally,
and never experienced a similar episode. One patient
(2859) died of intractable lactic acidosis and multiple
organ failure. During the acute phase, there was usually
no indication of extrahepatic involvement, as evidenced
by normal electrolytes, creatinine and renal function,
blood count, bone marrow aspiration, creatine phosphoki-
nase (CPK), electromyography (EMG), echocardiogram,
ophthalmologic examination, brain magnetic resonance
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Table 1. Clinical and Biochemical Data of the Patients
Patient Origin Age at Presentation Outcome
Peak Values
ALT (IU/L) GGT (IU/L) INR T-Bil (mg%) Lactate (mM)
2624 Y-J 6 mo A&W at 2 yrs 367 356 2.6 3.3 5.5
3032 Y-J 4 mo A&W at 9 mo 169 621 5.7 4.5
1432 Y-J 2 mo A&W at 10 yrs 1150 3.4 10 20
1116 Y-J 3 mo A&W at 10 yrs 293 139 9.7 6.6
111 Y-J 4 mo A&W at 8 yrs 417 3.0 7.0
421 Y-J 4 mo A&W at 14 yrs 430 3.0 4.3 20
2859 Y-J 3 mo death at 4 mo 400 157 7.0 24.0 30
2375 Y-J 6 mo A&W at 2 yrs 532 305 3.6 7.5 3.2
2006 Arab 1 mo death at 2 mo 1193 77 3.4 14.4 19
3015 Arab 6 mo A&W at 2 yrs
1910 Ashk. 1 day A&W at 5 yrs 1146 270 2.3 0.1 20
Akh Alger 1 day death at 3 mo 93 13.2 7.0
Aza Alger 2 days death at 4 mo 229 6.3 10.0
control <52 <142 <1.0 <0.4 <2
Abbreviations are as follows: ALT, alanine aminotransferase; GGT, gamma glutamyl transpeptidase; T-Bil, total bilirubin; INR, international normalized ratio; Y-J,
Yemenite Jewish; Ashk, Ashkenazi-Jewish; Alger, Algerian; A&W, alive and well.conduction velocity (NCV). An exception was patient
1116, who suffered from dilated cardiomyopathy with
impaired myocardial contractility and from nephromegaly
with massive proteinuria that resolved only after several
months.
During the acute phase, liver biopsy, performed in two
patients, revealed minimal chronic inﬂammation and
mild focal proliferation of bile ductules with variable portal
and sinusoidal ﬁbrosis. In the parenchyma, extensive
oncocytic change in the hepatocytes was noted, as well
as focal macrovesicular steatosis and focal ballooning of402 The American Journal of Human Genetics 85, 401–407, Septemtheir cytoplasm (Figure 1A). Iron stain revealed slight
accumulation of pigment, primarily within the hepato-
cytes. In the liver sample of patient 3015, obtained when
the patient was 9 months of age, during which time the
patient was still symptomatic, the liver architecture was
markedly disrupted by micronodule formation separated
by delicate ﬁbrous septae. The nodules were composed of
enlarged hepatocytes, with thickening of the liver plates
and hepatocanalicular cholestasis (Figure 1B). The patho-
logical and histochemical examinations of muscle tissue
obtained from three patients were invariably normal.Figure 1. Histopathological Findings in Liver Tissue
(A) Liver tissue showing marked oncocytic change in the hepatocytes (arrow) and focal ballooning degeneration of hepatocytes (arrow-
head) (H&E).
(B) Hepatic tissue with markedly disrupted architecture characterized by nodule formation with prominent sinusoidal ﬁbrosis (Masson
Trichrome stain).ber 11, 2009
Table 2. Mitochondrial Enzymatic Activities, mtDNA Content, and TRMU Genotype of the Patients
Patient Tissue Citrate Synthase Complex I Complex II Complex IIþIII Complex IV mtDNA Content TRMU Genotype
2624 L 270% 29% 66% 43% 15% Y77H/Y77H
M 21% 71% 95% 76% 47%
3032 L 238% 7% 51% 8% 22% 143% Y77H/Y77H
1432 L 211% 75% 34% 10% 78% Y77H/a
M 38% 132% 108% 86%
1116 L* 65% 260% 141% 103% Y77H/Y77H
M 64% 75% 63% 60%
111 N.A. Y77H/Y77H
421 N.A. Y77H/Y77H
2859 L 208% 11% 65% 12% 16% 380% Y77H/c.706-1G>Ab
2375 N.A. L233F/A10S
2006 L 148% 25% 70% 17% 250% V279M/c.500-510del
3015 L 302% 8% 80% 39% 14% 104% G272D/G272D
1910 M 75% 42% 97% 89% 29% 107% G14S/c
Akh M 12% 44% 17% M1K/M1K
Aza M 68% 14% 47% 22% 38% M1K/M1K
Tissue samples (L, liver; M, muscle) were obtained during the acute phase, with the exception of patient 1116, whose liver (L*) was obtained 6 mo after the acute
episode. N.A. denotes not available. All enzymatic activities are given as a percentage of the control mean and are normalized for citrate synthase activity. The
citrate synthase activity and mtDNA content are given as a percentage of the control mean.
a A second mutation was not identified in the 11 exons of the TRMU gene, and cDNA of this patient was not available.
b This mutation resulted in exon 3 skipping (107 bp).
c The patient was heterozygous for the G14S mutation, but the patient’s cDNA consisted of only the paternal allele carrying this mutation.The enzymatic activities of the mitochondrial respira-
tory chain complexes I–IV in liver homogenate and in
mitochondria isolated from the patients’ muscles were
determined by standard spectrophotometric methods.4
In liver obtained during the acute phase, the activities of
complexes I, III, and IV normalized to citrate synthase
activity were markedly reduced; only complex II activity
was relatively preserved (Table 2). Themitochondrial respi-
ratory chain activities were normal in homogenate of the
liver tissue obtained six months after the onset of the acute
episode in patient 1116. In mitochondria isolated from the
acute phase muscle tissue, only complex IV activity was
slightly reduced.
The markedly reduced activities of complexes I, III, and
IV in liver homogenate and the relatively normal activity
of complex II—the only complex that is encoded solely
by the nuclear genome—suggested a defect in the
synthesis of the mtDNA-encoded proteins. The normal
ratio of mtDNA to nuclear DNA in the patients’ liver, as
determined by real-time PCR (Table 2), ruled out mtDNA
depletion. The mtDNA transcription was investigated in
patient 2859 ﬁbroblasts by determination of the abun-
dance of the 12S and 16S rRNA transcripts and of the
COX2 mRNA. The normal results of these analyses (data
not shown) not only indicated intact transcription but
have also excluded a defect in themitochondrial ribosomal
assembly, which would lead to a severe reduction of theThe AmericanrRNA transcripts.5 Assuming a defect in mitochondrial
translation, we determined the sequence of the 22 mito-
chondrial tRNA genes and the two rRNA genes in patient
2859 liver but did not identify any mutation, suggesting
a defect in a nuclear-encoded mitochondrial translation
factor. We next quantiﬁed mitochondrial translation by
pulse-chase incorporation of 35S-methionine into mito-
chondrially synthesized polypeptides in ﬁbroblasts of
three patients, in the presence of 0.5 mg/ml of emetine
for inhibition of cytoplasmic translation, as previously
described.6 To assure correct quantiﬁcation, we performed
immunoblotting of tubulin in the same samples. In all
three patients’ ﬁbroblasts, the overall mitochondrial trans-
lation level was reproducibly twice lower than that in
control cells (Figure 2).
In order to localize the mutated gene, we performed
homozygosity mapping with the DNA of patients 3032
and 2624, using the GeneChip Human Mapping 250K
NspArray of Affymetrix, as previously described.8 All exper-
iments involving DNA of the patients, their relatives,
healthy controls, and patients’ cells were approved by the
Hadassah Ethical Review Committee. This analysis dis-
closed two nonoverlapping homozygous regions > 5 Mb
in each sample. The only genomic region of identical
homozygous markers was a 3.06 Mb region on chromo-
some 22, from 43.49 Mb to 46.55 Mb, which included 223
SNP markers (from rs5765930 to rs7292036). Within thisJournal of Human Genetics 85, 401–407, September 11, 2009 403
region, therewere 27 open reading frames, includingTRMU
(MIM 610230), which encodes the mitochondria-speciﬁc
tRNA-modifying enzyme, tRNA 5-methylaminomethyl-2-
thiouridylate methyltransferase. Sequence determination
of the 11 exons of TRMU and their ﬂanking intronic
regions identiﬁed a homozygous mutation, c.232T>C,
which changes the highly conserved Tyr77 to His (Y77H).
Five patients were homozygous for the mutation and two
were heterozygous. Because the mutation created an MslI
Figure 2. Analysis of Mitochondrial Translation in the Patients’
Fibroblasts
The mitochondrial translation products on SDS-PAAG are indi-
cated according to a standard pattern.7 Assays were performed in
the ﬁbroblasts of a control (lane 1) and three patients (lanes 2–4
for patients 2624, 2859, and 1910, respectively). The relative
values were normalized to tubulin (panel below the autoradio-
graphs) and are presented as a diagram. Error bars represent the
results of two independent experiments.404 The American Journal of Human Genetics 85, 401–407, Septemrestriction site, we used this enzyme for the screening of
120 anonymous individuals of Yemenite Jewish origin
and identiﬁed three carriers. Patient 2859, who was hetero-
zygous for the Y77H mutation on the maternal allele,
carried a second mutation, c.706-1G>A, on her paternal
allele, which resulted in skipping of exon 3. The only Yem-
enite Jewish patient who did not carry the Y77Hmutation,
patient 2375, was compound heterozygous for c.697C>T
(L233F) and c.28G>T (A10S), both changing highly
conserved residues. Because the patient cDNA and parental
DNA were not available, we could not assign the phase of
the mutations. We then screened the TRMU gene for muta-
tions in DNA of patients of non-Yemenite-Jewish origin
who presented with infantile liver failure and a similar
pattern of respiratory chain defects and identiﬁed ﬁve addi-
tional mutations in ﬁve unrelated patients (Table 1 and
Table 2). Four mutations, c.2T>A (M1K), c.40G>A (G14S),
c.835G>A (V279M), and c.815G>A (G272D), changed
highly conserved residues, and the ﬁfth, c.500-510del,
was a frame-shift mutation. Patient 1910 carried the G14S
mutation on his paternal allele, but homozygosity for this
mutation was present in cDNA produced from his ﬁbro-
blasts, suggesting a nonexpressing maternal allele. No
mutation was detected in the promoter region and at the
~1100 nucleotide, which separates TRMU from the neigh-
boring 50 gene. The M1K mutation was identiﬁed in two
Algerian patients, the G14S mutation was found in an
Ashkenazi Jewish patient, and the rest of the mutations
were detected in patients of Arabic ethnicity. We did not
detect any carrier for theM1Kmutation among106 individ-
uals of North African origin. Altogether, we identiﬁed nine
mutations in 13 patients who presented with acute liver
failure during infancy (Figure 3). Of note, no mutations
were detected in the TRMU gene of 17 unrelated patients
of North African, Jewish, and Arabic origin having a similar
pattern of enzymatic defects and presenting with isolated
mitochondrial liver disease immediately after birth, nor in
threepatientswithchronic extrahepatic involvement, indi-
cating thatmutations in theTRMU geneprimarily affect the
liver at a speciﬁc window of time.
ThehumanTRMU gene encodes 421-aa-longprotein that
participates in the modiﬁcation of mitochondrial tRNAs
and is therefore important for mitochondrial translation.
Speciﬁcally, it is responsible for the 2-thiolation of the
wobble position of the mitochondrial tRNA-Lys, tRNA-
Gln, and tRNA-Glu.We therefore studied the 2-thiouridyla-
tion at the wobble nucleotide of these three tRNAs in
patients 2624, 2859, and 1910. This was tested by retarda-
tion in an electrophoretic system consisting of a 10%
PAAG with 7 M urea, tris-borate buffer polymerized in the
presence of 50 mg/ml of (N-)Acroylamino-phenyl-mercuric
chloride) (APM), which was synthesized by the procedure
described by Igloi.9 Total cellular RNA was isolated with
Trizol-reagent (Invitrogen). RNA hybridization was per-
formed as described by Shigi et al.,10 with the following
[32P]-50-end-labeled oligonucleotide probes: mt-tRNA-Lys,
GGTTCTCTTAATCTTTAAC; mt-tRNA-Glu, CCACGACCAber 11, 2009
Figure 3. The Mutations Identified in the TRMU Gene
The mutations identiﬁed in the TRMU gene of patients with acute liver failure, depicted on a schematic representation of the conserved
domains (NCBI conserved domains website). G14 is one of six residues (red arrowheads) that form the P loop motif (SGGXDS), which is
an ATP-binding motif commonly found in enzymes responsible for RNA modiﬁcations.14ATGATATG; mt-tRNA-Gln, CGAACCCATCCCTGAG, and
cy-tRNA-Lys, ACTTGAACCCTGGACC. In this system, the
thiolated tRNAs are covalently retainedbyHg-groups incor-
porated in the polyacrylamide gel and have lower mobility
than nonthiolated ones. For the purpose of quantiﬁcation,
hybridizations were performed in parallel after separation
of the same samples on gels without APM. The results
of this analysis clearly disclosed that the amount of the
thio-modiﬁed mitochondrial tRNAs is severely reduced in
all three patients, whereas the pattern of hybridization
obtained for the cytosolic tRNA (cy-tRNA-Lys) modiﬁed
by another enzyme was similar in control and patient cells
(Figure 4). Finally, the pattern of hybridization obtained for
the mitochondrial tRNA-Leu, which is not subjected to
thio-modiﬁcation, was similar in control and patient cells
(data not shown).
To study the effect of the hypomodiﬁcation on tRNA
stability, we performed RNA hybridization of total RNA
extracted from the patients’ ﬁbroblasts. This analysis dis-
closed slightly lower levels of several tRNAs, which was
nonspeciﬁc for the thio-modiﬁed tRNAs (Figure 5). We
therefore conclude that the TRMUmutations did not affect
either the transcription level or the stability of the hypo-
modiﬁed tRNAs to a signiﬁcant extent.
In view of these ﬁndings, we propose that the mitochon-
drial translation defect in our patients is the result of
reduced modiﬁcation of several mitochondrial tRNAs. InThe AmericanE. coli, the 2-thiouridylation stabilizes the codon-anticodon
interaction and confers the tRNA an efﬁcient ribosome
binding.11,12 Until now, only one mutation in the human
TRMU gene, A10S, had been reported. Homozygosity
for this mutation had aggravated the deafness phenotype
of patients who harbored the homoplasmic A1555Gmuta-
tion in the mitochondrial gene encoding the 12S rRNA,
MTRNR1 (MIM 561000). The combination of TRMU and
MTRNR1mutations was associated with reduced 2-thiouri-
dylation and low content of the mitochondrial tRNAs,
which led to impaired mitochondrial protein synthesis.13
The TRMUprotein requires sulfur for its activity; cysteine
desulfurase, which transfers sulfur from cysteine to the
TRMU ortholog, has been shown to be essential for the
thio-modiﬁcation of bacterial tRNAs.14 The availability of
cysteine in the neonatal period is limited because its endog-
enous synthesis from methionine by the transsulfuration
pathway is markedly attenuated. The activity of the rate-
limiting enzyme in the pathway, cystathionase, is very
low at birth and increases slowly during the ﬁrst few
months of life.15 For this reason, cysteine is considered
a conditionally essential amino acid, at least in preterm
infants. Furthermore,metallothionein, a sourceof cysteine,
is at its peak at birth and declines rapidly during the ﬁrst
month of life.16 We propose that there is a window of
time, during 1–4 months of age, whereby patients with
TRMUmutations are at an increased risk of developing liverJournal of Human Genetics 85, 401–407, September 11, 2009 405
Figure 4. Thio-Modification in Mito-
chondrial tRNAs
Analysis of thio-modiﬁcation at position 2
of the wobble uridine via RNA hybridiza-
tion of mitochondrial (mt-tRNA-Lys,
mt-tRNA-Glu, andmt-tRNA-Gln) and cyto-
plasmic (cy-tRNA-Lys) tRNAs separated in
APM-containinggels (þAPM,upper panel).
For quantiﬁcation, the same amount of
RNA obtained from patient and control
ﬁbroblasts was separated in gels without
APM (-APM, middle panel). The retarded
diffused zones correspond to the thiolated
and nonthiolated versions of each tRNA
(Thiolated and Nonthiolated, respec-
tively). The hybridization probes and the
numbers of the RNA samples are indicated
at the top of the autoradiographs; the
numbers correspond to the samples
describedunder the diagramat the bottom.
The quantiﬁcation of the modiﬁcation is
presented at the bottom panel and is
expressed as a percentage of the thiolated
signal from the thiolated þ nonthiolated
signals (as presented in the -APM gel at
the middle panel), normalized against the
control ﬁbroblasts. The deviations are indi-
cated as a result of two to three indepen-
dent measures (for the control ﬁbroblasts,
the deviation was quasi null and is there-
fore not indicated).failure. Dietary- andmetallothionein-derived cysteine may
provide some protection during the ﬁrst month of life, and
the rising activity of cystathionase serves a similar purpose
after 3–4 months of age. Nonetheless, an intercurrent
illness combined with reduced dietary (cysteine) intake at
1–4months of agemay further compromise TRMU activity
in these patients. This may account for the timing of the
clinical presentation, mostly at 2–4 months of age, and
the lack of recurrence in patients who survive the neonatal
episode. Sequence determination of the TRMU gene is war-
ranted in patients with acute liver failure in the ﬁrst year of
life, predominantlywhen the onset is at 1–4months of age.
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